Analyst Ratings For Agile Therapeutics (NASDAQ:AGRX)
Today, Janney Montgomery Scott reiterated its Buy rating on Agile Therapeutics (NASDAQ:AGRX) with a price target of $15.00.
There are 6 buy ratings on the stock.
The current consensus rating on Agile Therapeutics (NASDAQ:AGRX) is Buy (Score: 3.00) with a consensus target price of $11.17 per share, a potential 115.16% upside.
Some recent analyst ratings include
- 7/21/2017-Janney Montgomery Scott Reiterated Rating of Buy.
- 7/19/2017-HC Wainwright initiated coverage with a Buy rating.
- 6/14/2017-Noble Financial Reiterated Rating of Buy.
- 5/8/2017-Cantor Fitzgerald Reiterated Rating of Buy.
- 11/10/2015-William Blair Reiterated Rating of Buy.
Recent Insider Trading Activity For Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics (NASDAQ:AGRX) has insider ownership of 3.50% and institutional ownership of 79.78%.
- On 5/11/2017 Alfred Altomari, Chairman, bought 10,000 with an average share price of $3.51 per share and the total transaction amounting to $35,100.00. View SEC Filing
- On 5/11/2017 Renee Selman, Insider, bought 53,333 with an average share price of $3.68 per share and the total transaction amounting to $196,265.44. View SEC Filing
- On 1/27/2016 Jay Moorin, Major Shareholder, bought 393,700 with an average share price of $6.35 per share and the total transaction amounting to $2,499,995.00. View SEC Filing
- On 6/2/2015 Alfred Altomari, CEO, bought 2,500 with an average share price of $8.73 per share and the total transaction amounting to $21,825.00. View SEC Filing
- On 1/23/2015 Jay Moorin, Major Shareholder, bought 811,966 with an average share price of $5.85 per share and the total transaction amounting to $4,750,001.10. View SEC Filing
- On 5/29/2014 Care Capital Iii Llc, Major Shareholder, bought 500,000 with an average share price of $6.00 per share and the total transaction amounting to $3,000,000.00. View SEC Filing
- On 5/23/2014 Andrew N Schiff, Director, bought 1,333,333 with an average share price of $6.00 per share and the total transaction amounting to $7,999,998.00. View SEC Filing
Recent Trading Activity for Agile Therapeutics (NASDAQ:AGRX)
Shares of Agile Therapeutics closed the previous trading session at 5.19 down -0.18 -3.35% with 208,626 shares trading hands.